Novo Nordisk launches popular weight-loss drug Wegovy in Germany

The Danish drugmaker's share price has more than doubled in the two years since the drug debuted, turning Novo into Europe's second-most-valuable listed company after Louis Vuitton.

Injections of Wegovy start at €170 a month, rising to more than €300 as treatment requires the dosage to increase.

Novo Nordisk has popular blockbuster weight-loss drug Wegovy in Germany, its first big European market, hoping Germans will pay hundreds of euros for the drug. 

The drug has been shown to help patients reduce their body weight by around 15% when used along with exercise and lifestyle changes. It is already available in the US, but so far in Europe it is on sale only in the relatively small markets of Norway and Denmark.